Skip to main content
Article
Lasmiditan for the Treatment of Migraines With or Without Aura in Adults.
Psychopharmacology Bulletin
  • Amnon A. Berger, Beth Israel Deaconess Medical Center
  • Ariel Winnick, Soroka University
  • Daniel Popovsky, Georgetown University School of Medicine
  • Alicia Kaneb, Georgetown University School of Medicine
  • Kevin Berardino, Georgetown University School of Medicine
  • Adam M. Kaye, University of the Pacific
  • Elyse M. Cornett, Louisiana State University
  • Alan David Kaye, Louisiana State University Health Science Center
  • Omar Viswanath, University of Arizona College of Medicine – Phoenix
  • Ivan Urits, Louisiana State University Health Sciences Center - Shreveport
ORCiD
Adam M. Kaye: 0000-0002-7224-3322
Document Type
Article
Publication Date
10-15-2020
Abstract

Migraines are a common form of primary headache, affecting women more than men (17.4% and 5.7% of US population, respectively, a total of 12%) that carry significant morbidity and disability, as well as a hefty healthcare price tag. They are most prevalent in women of reproductive ages and are estimated to be the 6th disease in order of causing global burden. They are estimated to cause 45.1 million years lived with disability, or 2.9% of global years lost to disability. Migraine treatment divides into acute, abortive treatment for relief of an ongoing migraine attack, and prophylactic therapy to reduce the occurrence of migraines, specifically for patients suffering from chronic and frequent episodic migraines. Traditional abortive treatment usually begins with NSAID and non-specific analgesics that are effective in curbing mild to moderate attacks. 5HT

Citation Information
Amnon A. Berger, Ariel Winnick, Daniel Popovsky, Alicia Kaneb, et al.. "Lasmiditan for the Treatment of Migraines With or Without Aura in Adults." Psychopharmacology Bulletin Vol. 50 Iss. 4 Suppl 1 (2020) p. 163 - 188 ISSN: 2472-2448
Available at: http://works.bepress.com/adam-kaye/77/